Stacy L. Moulder, MD, professor of breast medical oncology at MD Anderson Cancer Center, discusses the challenges in drug development for triple-negative breast cancer (TNBC), specifically in the neoadjuvant setting.
Approximately 50% of patients with TNBC are sensitive to standard chemotherapy, says Moulder, and they do not need the additional toxicities of certain investigational agents.
Moulder discusses a poster presented at the 2018 San Antonio Breast Cancer Symposium where patients with TNBC were started on chemotherapy before identifying who was sensitive using imaging from ultrasound-based assessments.
Patients who did respond to treatment had a complete response at the time of their surgery. However, further analysis is planned for the patients that did not respond. Moulder says next steps include separating them into subtypes of TNBC to find the best appropriate therapies.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
